Evaluation of pantoprazole formulations in different dissolution apparatus using biorelevant medium

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 1, 2010, Pages 42-47

  De Campos, Daniel Rossi ^a,b   Klein, Sandra ^c   Zoller, Thomas ^c   Vieria, Nelson Rogério ^a   Barros, Fábio Alessandro Proença ^a   Meurer, Eduardo César ^a   Coelho, Edvaldo Capobiango ^a   Marchioretto, Marco Antônio ^a   Pedrazzoli, José ^a,b  

^a Universidade Sao Francisco Centro de Ciencias Biologicas e da Saude   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Biopharmaceutics classification system; Biorelevant dissolution testing; CAS 102625 70 7; In vitro in vivo correlation; Pantoprazole

Indexed keywords

CAS 102625 70 7; PANTOPRAZOLE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 74949116822     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296247     Document Type: Article

References (36)

1. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698-705.
2. Klein S, Stein J, Dressman JB. Site-specific delivery of antiinflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol. 2005;57:709-19.
3. Klein S. Biorelevant Dissolution Test Methods for Modified Release Dosage Forms. Frankfurt (Main): Institut für Pharmazeutische Technologie, Johann Wolfgang Goethe-Universität; 2005. p. 1-280.
4. Shah S, Lesko LJ. Current challenges and future regulatory directions in in vitro dissolution. Drug Inform J. 1995;19:885-91.
5. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); October 1997.
6. Polli JE. IVIVR vs. IVIVC. Dissol Technol. 2000;7:6-16.
7. Guidance for Industry. Dissolution Testing for Immediate Release Solid Oral Dosage Forms. U.S Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); October 1997.
8. Guia para validação de métodos analíticos e bioanalíticos. Brazil: Agência Nacional de Vigilância Sanitária (ANVISA); April 2003.
9. USP 29. United States Pharmacopeia. Rockville (MD): United State Pharmacopeia Convention, Inc.; 2006.
10. Li J, Yang L, Ferguson SM, Hudson TJ, Watanabe S, Katsuma M, et al. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES™) in multi-pH media using United States pharmacopeia apparatus II and III. AAPS PharmSci Tech. 2002;3:E 33.
11. Cacace J, Reilly EE, Amann A. Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP apparatus 2 and 3. AAPS PharmSci Tech. 2004;5:E6.
12. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. PharmRes. 1995;15:413-20.
13. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); October 2000.
14. Jantratid E, Prakongpan S, Amidon GL, Dressman JB. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet. 2006;45:385-99.
15. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essencial medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-78.
16. Blume HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? Eur J Pharm Sci. 1999;9:117-21.
17. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci. 2004;22:297-304.
18. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. PharmSci. 2004;93:1945-56.
19. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. Pharm Sci. 2005;94:1617-25.
20. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes and clinical practice. Pharmacol Res. 2006;58:521-90.
21. Campos DR, Vieira NR, Bernasconi G, Barros FAP, Meuer EC, Marchioretto MA, et al. Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Arzneimittelforschung. 2007;57(6):309-14.
22. Klein S, Butler J, Hempenstall JM, Reppas C, Dressman JB. Media to simulate the postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts. J Pharm Pharmacol. 2004;56:605-10.
23. 2. Pharm Res. 1998;15:889-96.
24. International Conference of Harmonisation of technical requirements for registration of pharmaceutical for human use. ICH Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2(R1); 1996.
25. Guia para planejamento e realização da etapa estatística de estudos de biodisponibilidade relativa/ bioequivalência. Brazil: Agência Nacional de Vigilância Sanitária (ANVISA); April 2003.
26. Polli JE, Crison JR, Amidon GL. Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci. 1996;85:753-60.
27. Dissolution methods for drug products [FDA website]. Rockville (MD): Food and Drug Administration (US); 2008 - [cited 2008 June 24]. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution
28. Rohrs BR, Burch-Clarck DL, Witt MJ, Stelzer DJ. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations. J Pharm Sci. 1995;84:922-6.
29. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Biowaiver extension potencial to BCS class III high-solubility low-permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci. 2004;22:297-304.
30. Ekpe A, Jacobsen T. Effect of various salts on the stability of lansoprazole, omeprazole and pantoprazole as determined by high-performance liquid chromatography. Drug Dev Ind Pharm. 1999;25:1057-65.
31. Polli JE. In vitro-in vivo relationships of several "immediate" release tablets. Adv Exp Med Biol. 423:191-8.
32. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sci. 2005;94:1617-25.
33. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci. 2006;95:974-84.
34. FIP. International Pharmaceutical Federation website; 2008 [cited 2008 June 24]. Available from: http://www.fip.org/
35. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-78.
36. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Mol Pharm. 2004;1:85-96.